ClinicalTrials.gg
Active, not recruitingNCT06875973Updated Oct 14, 2026

Pelacarsen Roll-over Extension Program

A Phase 3 interventional study of Pelacarsen (TQJ230) in Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 89 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Oct 14, 2026Now Active, not recruiting8 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
599
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Atherosclerosis by Novartis — 4 open to participants now, 10 under way, 3 of them phase 3. Atherosclerosis · Novartis.

Planned enrollment
6th of 18
599 · median 426
Started
2025
with 6 others
Phase 3
10 of 27
none open now
Registered
21st of 27
by date

Among the 27 studies in Atherosclerosis by Novartis, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 7 that started in 2025, is one of 10 in phase 3, and was the 21st registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

4 of the 27 studies in Atherosclerosis by Novartis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Atherosclerosis by Novartis, or all of them as a file.
02

Study summary

This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint.

Read the detailed description

This study will evaluate long-term safety and tolerability of pelacarsen (TQJ230) 80 mg Once a month (QM) in patients with elevated Lp(a) and established ASCVD. All consenting participants from the parent study who meet the eligibility criteria will be participating in this open label extension study.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease

Browse trials for

Keywords

  • TQJ230
  • Lp(a)
  • ASCVD
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have provided prior to initiation of any study-specific activities/procedures.
  • Participants who have completed the parent study and received the assigned study treatment at the time of its completion

Exclusion criteria

Exclusion Criteria:

  • Participants who permanently discontinued the study treatment as mandated per protocol or due to adverse events in the parent study
  • Any medical condition(s) in the investigator's opinion that may put the participant at risk or interfere with the study participation
  • Participants who are receiving another drug or device before the open-label treatment period
  • Participants who have a known sensitivity to the study drug and are deemed as unsuited for the study by the investigator

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
599 participants (estimated)

Study arms

  • Experimental
    Pelacarsen (TQJ230)

    open-label pelacarsen 80mg

    Drug: Pelacarsen (TQJ230)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse events (AEs) or serious adverse events (SAEs)

    Evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants with elevated Lp(a) and established atherosclerotic cardiovascular disease who have completed the parent study

    Time frame: Up to 48 months

Secondary outcomes

  1. Observed value and change in Lipoprotein(a) (Lp(a)) compared to baseline of the parent study

    Evaluate the long-term efficacy of pelacarsen (TQJ230) in lowering Lp(a) levels

    Time frame: Baseline of the core study, Month 3, 12, 24, 36, 48

  2. Observed value and change in Lp(a) compared to baseline of the rollover extension program (REP) study

    Evaluate the long-term efficacy of pelacarsen (TQJ230) in lowering Lp(a) levels

    Time frame: Baseline of the REP study, Month 3, 12, 24, 36, 48

07

Study locations

89 sites
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2030, 66 months after the start.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 66 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 14, 2025
StartActual
May 19, 2025
Primary completionEst.
Dec 8, 2030
CompletionEst.
Dec 8, 2030
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 14, 2026
Sites
8 sites removed
Show 8 removed
  • Proactive Clinical Research · Fort Lauderdale, United States
  • Inpatient Research Clinical LLC · Miami Lakes, United States
  • Flourish Research · Winter Park, United States
  • Dallas Heart and Vascular Consultants PA · Houston, United States
  • Dallas Heart and Vascular Consultants PA · Houston, United States
  • Javara Research · Alexandria, United States
  • Javara Research · Alexandria, United States
  • Javara Research · Alexandria, United States
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Active, not recruiting
    8 sites removed
    Show 8 removed
    • Proactive Clinical Research · Fort Lauderdale, United States
    • Inpatient Research Clinical LLC · Miami Lakes, United States
    • Flourish Research · Winter Park, United States
    • Dallas Heart and Vascular Consultants PA · Houston, United States
    • Dallas Heart and Vascular Consultants PA · Houston, United States
    • Javara Research · Alexandria, United States
    • Javara Research · Alexandria, United States
    • Javara Research · Alexandria, United States
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06875973
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
May 19, 2025
Primary completion
Dec 8, 2030 (estimated)
Completion
Dec 8, 2030 (estimated)
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelacarsen

Start the discussion